Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial
- 1 January 2010
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 375 (9708), 56-66
- https://doi.org/10.1016/s0140-6736(09)62003-1
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- A Novel Influenza A (H1N1) Vaccine in Various Age GroupsNew England Journal of Medicine, 2009
- Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted VaccineNew England Journal of Medicine, 2009
- Response to a Monovalent 2009 Influenza A (H1N1) VaccineNew England Journal of Medicine, 2009
- Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza VirusNew England Journal of Medicine, 2009
- Serologic Survey of Pandemic (H1N1) 2009 Virus, Guangxi Province, ChinaEmerging Infectious Diseases, 2009
- Immunogenicity, Safety, and Cross?Reactivity of an Inactivated, Adjuvanted, Prototype Pandemic Influenza (H5N1) Vaccine: A Phase II, Double?Blind, Randomized TrialClinical Infectious Diseases, 2009
- A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell CultureNew England Journal of Medicine, 2008
- Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trialThe Lancet, 2006
- Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trialThe Lancet, 2006